Cover Image
Market Research Report

Global Markets for Infectious Disease Treatments

Published by BCC Research Product code 117624
Published Content info 197 Pages
Immediate Delivery Available
Price
Back to Top
Global Markets for Infectious Disease Treatments
Published: January 1, 2016 Content info: 197 Pages
Description

REPORT HIGHLIGHTS

The global market for infectious disease diagnostic, vaccine, and treatment products reached $108.4 billion in 2015. The market should reach $126.2 billion in 2016 and $183.2 billion in 2021, demonstrating a compound annual growth rate (CAGR) of 7.7% from 2016 to 2021.

This report provides:

  • An overview of the global market for infectious disease treatments, with a focus on the growth in demand for newer pharmaceutical treatments, vaccines, and environmental products.
  • Analyses of global market trends, with data from 2014, estimates for 2015, and projections of compound annual growth rates (CAGRs) through 2021.
  • Discussion of the increasing concern regarding antibiotic-resistant organisms and their sometimes-fatal effects on humans.
  • Examination of technological developments, future trends, and emerging opportunities.
  • Assessments of the current state of infectious diseases on a global basis, broken down by type of disease (i.e., bacterial, viral, parasitic, and fungal) and appropriate treatments, both current and anticipated, and by geographic region.
  • A relevant patent analysis.
  • Profiles of major players in the field of infectious disease treatments.

SCOPE OF REPORT

The market report organizes information from diverse sources into a cohesive unit that includes an overview, global implications of infectious diseases, infectious diseases by type, treatment and prevention, emerging pharmaceutical and diagnostic products and an applicable patents section. Information is organized by type of infectious disease (i.e., bacterial, viral, parasitic) and appropriate treatments, both current and anticipated.

ANALYST'S CREDENTIALS

Peggy Lehr is the BCC Research analyst for this report. Ms. Lehr holds a BS in Journalism from the University of Colorado, Boulder, and an MS in Communication from the University of Denver. Ms. Lehr has worked as a researcher, editor and publisher within the publishing industry for both for-profit and not-for-profit organizations. She is the author of several BCC reports dealing with healthcare, pharmaceuticals and agriculture. Her latest report, BIO145A The U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments was published in Aug. 2015.

Table of Contents
Product Code: PHM061C

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE OF REPORT
  • INTENDED AUDIENCE
  • METHODOLOGIES AND INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - SUMMARY

  • SUMMARY TABLE: GLOBAL MARKET FOR INFECTIOUS DISEASES DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL MARKET SHARE FOR INFECTIOUS DISEASE DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PRODUCTS, 2016 AND 2021 (%)

CHAPTER 3 - OVERVIEW OF THE GLOBAL STATE OF INFECTIOUS DISEASE DIAGNOSIS, VACCINES AND TREATMENT

  • TOP GLOBAL CAUSES OF DEATH
    • TABLE 1: GLOBAL PERCENTAGE OF DEATHS BY TYPE OF DISEASE, CAUSE, INCOME LEVEL, 2012* (%)
  • MAJOR INFECTIOUS DISEASES
    • TABLE 2: SELECTED WORLDWIDE MAJOR INFECTIOUS DISEASES, 2013* (NUMBER OF CASES, TREATMENT OPTIONS)
  • HISTORICAL IMPACT OF INFECTIOUS DISEASES
    • LEADING CAUSES OF GLOBAL DEATHS
      • Transmission of Infectious Diseases
    • LINKING INFECTIOUS DISEASE TO CANCER
  • TREATMENTS FOR INFECTIOUS DISEASES
    • PREVENTION
    • VACCINATION
      • WHO Global Vaccination Action Plan
        • FIGURE 1: GLOBAL IMMUNIZATION COVERAGE, 2014 (%)
      • Challenges to Meet WHO Guidelines
  • GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET
  • TYPES OF DIAGNOSTIC TESTING
    • FLUORESCENT IMMUNOASSAY (FIA)
      • Direct Fluorescent Antibody Testing (FA)
      • Indirect Fluorescent Antibody Testing (IFA)
    • ENZYME IMMUNOASSAY (EIA)
      • Basic EIA
      • Enzyme-Linked Immunosorbent Assay (ELISA)
    • GENE PROBE ANALYSIS
      • Polymerase Chain Reaction Amplification (PCR)
      • Nucleic Acid Amplification Test (NAT)
      • Transcription-Mediated Amplification (TMA)
      • Nucleic Acid Sequence-Based Amplification (NASBA)
  • GLOBAL MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
    • TABLE 3: GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, THROUGH 2021 ($ MILLIONS)
  • GLOBAL INFECTIOUS DISEASE VACCINE MARKET
    • TABLE 4: GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE VACCINE PRODUCTS, THROUGH 2021 ($ MILLIONS)
  • GLOBAL INFECTIOUS DISEASE PHARMACEUTICAL MARKET
    • TABLE 5: GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
  • VACCINE OPPORTUNITIES
    • CHILDHOOD DISEASES
    • GLOBAL HUMANITARIAN AGENCIES
  • PHARMACEUTICAL OPPORTUNITIES
  • THE EMERGENCE OF GENE THERAPY
  • MERGERS AND ACQUISITIONS
    • TABLE 6: SELECTED MERGERS AND ACQUISITIONS, 2012 TO 2015 ($ MILLIONS)

CHAPTER 4 - VACCINES - THE PRESENT AND THE FUTURE

  • VACCINES AND PATENTS
  • MARKET FOR HUMAN INFECTIOUS DISEASE VACCINES
    • TABLE 7: GLOBAL MARKET FOR INFECTIOUS DISEASE VACCINE PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • TABLE 8: GLOBAL MARKET FOR INFECTIOUS DISEASE VACCINES BY DISEASE, THROUGH 2021 ($ MILLIONS)
  • TYPES OF VACCINES
    • LIVE ATTENUATED VACCINE
    • INACTIVATED VACCINE
      • Acellular/Subunit Vaccines
  • IMMUNITY
    • INNATE IMMUNITY
    • ACQUIRED IMMUNITY
      • The Activity of T Cells
      • Acquired Immunity - Cell-Mediated Response
    • LASTING IMMUNITY
  • VIRAL DISEASES PREVENTED BY VACCINE
    • TABLE 9: VIRUSES, THE DISEASES THEY CAUSE, AND AVAILABLE VACCINES
  • BACTERIAL DISEASES PREVENTED BY VACCINE
    • TABLE 10: BACTERIA, THE DISEASES THEY CAUSE, AND AVAILABLE VACCINES
  • VACCINATION SCHEDULES FOR CHILDREN IN THE U.S.
    • TABLE 11: IMMUNIZATION SCHEDULE FOR CHILDREN FROM BIRTH TO 6 MONTHS IN THE U.S.
    • TABLE 12: IMMUNIZATION SCHEDULE FOR CHILDREN FROM 12 MONTHS, TO
  • YEARS TO 6 YEARS IN THE U.S.
    • TABLE 13: IMMUNIZATION SCHEDULE FOR CHILDREN AND ADOLESCENTS FROM
  • YEARS TO 18: YEARS IN THE U.S.
  • CONCERNS REGARDING VACCINATION IN CHILDHOOD
  • NUMBER OF INOCULATIONS
  • RECOGNIZING IMMUNE RESPONSE
  • IMMUNIZATION AND WEAKENED OR ALTERED IMMUNE SYSTEMS
  • HEPATITIS B VACCINATIONS THROUGH WHO GUIDELINES
  • VACCINE PRODUCTION
    • FIGURE 2: VACCINE MANUFACTURING PROCESS
  • VACCINE MANUFACTURERS
    • FIGURE 3: GLOBAL VACCINE MANUFACTURING MARKET, 2014 (%)
  • CHANGES IN MANUFACTURING LANDSCAPE
    • TOP-SELLING VACCINES OF 2014
      • TABLE 14: TOP-SELLING INFECTIOUS DISEASE VACCINES WITH APPLICATION, MANUFACTURER AND REVENUE, 2014
  • GLOBAL VACCINATION EFFORTS
    • REGIONAL ANALYSIS
      • TABLE 15: REGIONAL MARKETS FOR VACCINES, THROUGH 2021 ($ MILLIONS)
      • FIGURE 4: REGIONAL MARKET SHARE FOR VACCINES, 2016 AND 2021 (%)
    • THE AMERICAS
      • TABLE 16: AMERICAS MARKET FOR INFECTIOUS DISEASE VACCINES BY REGION, THROUGH 2021 ($ MILLIONS)
    • EMRA
      • TABLE 17: EMRA MARKET FOR INFECTIOUS DISEASE VACCINES BY REGION, THROUGH 2021 ($ MILLIONS)
    • ASIA
      • TABLE 18: ASIAN MARKET FOR INFECTIOUS DISEASE VACCINES BY REGION, THROUGH 2021 ($ MILLIONS)
  • TRENDS IN VACCINE DEVELOPMENT
    • ADJUVANT DEVELOPMENT
    • COMBINATION VACCINES
    • INHALED OR INTRANASAL VACCINE ADMINISTRATION
    • NEED FOR RAPID RESPONSE TIMES
      • Real-Time Detection

CHAPTER 5 - VIRAL INFECTIOUS DISEASES

  • GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS
    • TABLE 19: GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
  • PATENT PROTECTION
    • TABLE 20: PATENT EXPIRY BY PRODUCT, INDICATION, MANUFACTURER AND DATE OF PATENT EXPIRY
  • HEPATITIS B AND C
    • MARKET FOR HBV AND HCV DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS
      • TABLE 21: GLOBAL MARKET FOR HEPATITIS DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • DIAGNOSIS
      • TABLE 22: GLOBAL MARKET SHARE FOR HEPATITIS B AND C DIAGNOSTIC PRODUCT BY TYPE OF TEST AND REVENUES, 2015 ($ MILLIONS/%)
      • TABLE 23: CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HEPATITIS B AND C BY BRAND NAME AND MANUFACTURER, 2015
      • Automated Infectious Disease Testing for Hepatitis
    • TREATMENT MARKET
      • TABLE 24: GLOBAL MARKET FOR HEPATITIS B AND C TREATMENT MANUFACTURER MARKET STANDING BY REVENUES, 2015 ($ MILLIONS/RANK)
      • FIGURE 5: GLOBAL MARKET SHARE FOR TOP PHARMACEUTICAL MANUFACTURERS IN THE HEPATITIS MARKET, 2015 (%)
      • TABLE 25: PHARMACEUTICALS FOR THE TREATMENT OF HEPATITIS B AND C, 2015
    • NEWEST PHARMACEUTICALS TO TREAT HBV AND HCV
      • Additional Competitor
    • MARKET FOR DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS TO TREAT HBV AND HCV
      • TABLE 26: GLOBAL MARKET FOR HBV AND HCV PHARMACEUTICALS, THROUGH 2021 ($ MILLIONS)
  • RISK FACTORS
    • GEOGRAPHICAL DISTRIBUTION
    • HERPES SIMPLEX VIRUS
      • TABLE 27: GLOBAL MARKET FOR HSV DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
  • INCIDENCE
    • DIAGNOSIS
      • TABLE 28: CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HSV BY BRAND NAME, TYPE AND MANUFACTURER, 2015
    • TREATMENT
      • TABLE 29: DRUGS USED TO TREAT HSV BY BRAND NAME, GENERIC NAME AND MANUFACTURER
    • HIV/AIDS
      • TABLE 30: GLOBAL MARKET FOR HIV DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
  • RISK FACTORS
  • INCIDENCE/MORTALITY
  • ANTIRETROVIRAL THERAPY (ART)
  • HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)
    • TABLE 31: COMBINATION DRUGS APPROVED FOR HAART
    • HAART Failure
    • Mega-HAART
  • "TREATMENT FOR ALL" WHO PROGRAM
    • COUNT <800 CELLS/MEDICATIONS
      • Pre-Exposure Prophylaxis
  • CLINICAL TRIALS FOR HIV VACCINE AND MEDICATIONS
    • HUMAN PAPILLOMAVIRUS
      • TABLE 32: GLOBAL MARKET FOR HPV DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • HPV AND CANCER
      • TABLE 33: CANCERS LINKED TO HPV INFECTION, BY TYPE AND PERCENT OF FREQUENCY
  • INCIDENCE
  • SYMPTOMS
  • DIAGNOSIS
    • TABLE 34: CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HPV BY BRAND NAME, TYPE AND MANUFACTURER, 2015
  • TREATMENT
    • TABLE 35: DRUGS USED TO TREAT HPV BY BRAND NAME, GENERIC NAME AND MANUFACTURER
  • INFLUENZA A AND B
    • VACCINE
    • TREATMENT
  • CHILDHOOD DISEASES
    • MEASLES
    • MUMPS
    • POLIO
    • VIRAL PNEUMONIA
      • Treatment
  • ROTAVIRUS
    • DEHYDRATION
    • ZINC
  • RSV
    • SYMPTOMS
    • DIAGNOSTIC PRODUCTS
      • TABLE 36: RSV DIAGNOSTIC PRODUCTS BY BRAND NAME, MANUFACTURER AND TYPE, 2015
    • VIRAL DIAGNOSTIC PRODUCTS
      • TABLE 37: GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • VIRAL PHARMACEUTICAL PRODUCTS
      • TABLE 38: GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • REGIONAL ANALYSIS
      • TABLE 39: REGIONAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
      • FIGURE 6: REGIONAL MARKET SHARE FOR VIRAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, 2016 AND 2021 (%)
      • TABLE 40: REGIONAL MARKET FOR VIRAL DIAGNOSTIC PRODUCTS, THROUGH 2021 ($ MILLIONS)
      • TABLE 41: REGIONAL MARKET FOR VIRAL PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
  • AMERICAS
    • Hepatitis B in the U.S.
    • Hepatitis C in the U.S.
    • Market for Viral Infectious Disease Products in the Americas
      • TABLE 42: AMERICAS MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS BY REGION, THROUGH 2021 ($ MILLIONS)
      • TABLE 43: AMERICAS MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2021 ($ MILLIONS)
  • EMRA
    • Hepatitis C
    • Hepatitis in Africa
    • Hepatitis in Russia, Eurasia
    • Russian Pharmaceutical Regulations
    • Market for Viral Infectious Disease Diagnostic Products
      • TABLE 44: EMRA MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS BY REGION, THROUGH 2021 ($ MILLIONS)
      • TABLE 45: EMRA MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2021 ($ MILLIONS)
  • ASIA
    • Hepatitis in Asian Region
      • TABLE 46: CURRENTLY USED HEPATITIS DRUGS IN THE SOUTHEAST ASIAN REGION, BY PERCENT OF USE, 2012*
    • Hepatitis in Japan
    • Hepatitis in China
    • Hepatitis in India
    • HIV in Japan
    • HIV in India
    • HIV in China
      • TABLE 47: ASIAN MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS BY REGION, THROUGH 2021 ($ MILLIONS)
      • TABLE 48: ASIAN MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2021 ($ MILLIONS)

CHAPTER 6 - BACTERIAL INFECTIOUS DISEASES AND THE SPECTER OF ANTIBIOTIC RESISTANCE

  • NEGLECTED TROPICAL BACTERIAL INFECTIOUS DISEASES
    • TABLE 49: NEGLECTED TROPICAL BACTERIAL INFECTIOUS DISEASES
  • MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS
    • TABLE 50: GLOBAL MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
  • MARKET FOR BACTERIAL INFECTIOUS DISEASE DIAGNOSTICS
    • TABLE 51: GLOBAL MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTICS, THROUGH 2021 ($ MILLIONS)
  • MARKET FOR BACTERIAL INFECTIOUS DISEASES PHARMACEUTICALS
    • TABLE 52: GLOBAL MARKET FOR BACTERIAL INFECTIOUS DISEASES PHARMACEUTICALS, THROUGH 2021 ($ MILLIONS)
  • NOTABLE BACTERIAL DISEASES
    • SEXUALLY TRANSMITTED DISEASES
      • Chlamydia
    • INCIDENCE
    • DIAGNOSTIC PROCEDURES
      • TABLE 53: CURRENTLY AVAILABLE CHLAMYDIA TESTS BY BRAND NAME, TYPE AND MANUFACTURER, 2015
    • TREATMENTS
      • TABLE 54: CURRENT MEDICATIONS USED TO TREAT CHLAMYDIA
      • Gonorrhea
      • Diagnostic Product Market
        • TABLE 55: GONORRHEA DIAGNOSTIC PRODUCT AND MANUFACTURERS
      • Treatment Market
        • TABLE 56 MAJOR GONORRHEA TREATMENT MANUFACTURERS AND PRODUCTS
      • Syphilis
        • TABLE 57: STAGES OF SYPHILIS
      • Risk Factors
      • Incidence
      • Diagnostic Products
        • TABLE 58: CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF SYPHILIS BY BRAND NAME, TYPE AND MANUFACTURER, 2012
  • TREATMENTS
  • BACTERIAL PNEUMONIA
    • Treatment
  • CORYNEBACTERIUM DIPHTHERIAE, CLOSTRIDIUM TETANI, BORDETELLA PERTUSSIS
    • Diphtheria
    • Tetanus
    • Pertussis
  • MENINGITIS
    • MYCOBACTERIUM TUBERCULOSIS (TB)
      • TABLE 59: GLOBAL MARKET FOR TB DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
      • Epidemiology of TB
      • Geographic Prevalence
        • TABLE 60: GLOBAL MARKET FOR TB DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2021 ($ MILLIONS)
    • ANTIBIOTIC DEVELOPMENT
      • TABLE 61: ANTIBIOTICS: YEAR OF INTRODUCTION, YEAR OF RESISTANCE OBSERVED, MODE OF ACTION AND TARGET SPECIES
  • ANTIBIOTIC RESISTANCE
    • MECHANISMS OF RESISTANCE
    • METHODS OF RESISTANCE
      • Beta-Lactamase Production
      • Importing Resistance from Other Organisms
        • Examples of Antibiotic-Resistant Bacteria
      • Alteration of Binding Sites to Circumvent Anti-Infective Effectiveness
      • Antibiotic Discharge
    • PRIMARY REASONS FOR ANTIBIOTIC RESISTANCE
      • Failure to Finish Antibiotic Courses
      • Antibiotic Overuse
      • Agricultural Practices
        • TABLE 62: ANTIBIOTICS APPROVED FOR USE IN FOOD-PRODUCING ANIMALS BY DRUG CLASS, POUNDS USED, AND PERCENTAGE OF TOTAL, 2009* (POUNDS/%)
      • Patient Pressure
  • RESISTANCE BY CLASS OF ANTIBIOTIC
    • TABLE 63: ANTIBIOTIC-RESISTANT ORGANISMS AND DRUG CLASSES AFFECTED
  • INCIDENCES OF ANTIBIOTIC RESISTANCE
    • ANTIBIOTIC RESISTANCE IN EUROPE
    • ANTIBIOTIC RESISTANCE IN THE U.S.
  • MAJOR ANTIBIOTIC-RESISTANT ORGANISMS
    • VANCOMYCIN-RESISTANT ENTEROCOCCUS (VRE)
    • METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA)
    • CLOSTRIDIUM DIFFICILE (C. DIFFICILE)
  • REGIONAL ANALYSIS
    • TABLE 64: REGIONAL MARKET FOR BACTERIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • FIGURE 7: REGIONAL MARKET SHARE FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, 2016 AND 2021 (%)
  • THE AMERICAS
    • STDs in the U.S.
      • TABLE 65: AMERICAS MARKET FOR BACTERIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • Bacterial Infection Diagnostic Product Market in the Americas
      • TABLE 66: AMERICAS MARKET FOR BACTERIAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)
    • Bacterial Infection Pharmaceutical Market in the Americas
      • TABLE 67: AMERICAS MARKET FOR BACTERIAL INFECTION PHARMACEUTICAL PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)
  • EMRA (EUROPE, MIDDLE EAST, RUSSIA, AFRICA)
    • TABLE 68: EMRA MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • Bacterial Infectious Diseases Diagnostic Market in EMRA
      • TABLE 69: EMRA MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)
    • Bacterial Infectious Diseases Pharmaceutical Product Market in EMRA
      • TABLE 70: EMRA MARKET FOR BACTERIAL INFECTIOUS DISEASES PHARMACEUTICAL PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)
  • ASIA
    • TABLE 71: ASIAN MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • Bacterial Infectious Diseases Diagnostic Product Market in Asia
      • TABLE 72: ASIAN MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)
    • Bacterial Infectious Diseases Pharmaceutical Product Market in Asia
      • TABLE 73: ASIAN MARKET FOR BACTERIAL INFECTIOUS DISEASES PHARMACEUTICAL PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)

CHAPTER 7 - PARASITIC INFECTIOUS DISEASES

  • NEGLECTED TROPICAL PARASITIC INFECTIOUS DISEASES
    • TABLE 74: NEGLECTED TROPICAL PARASITIC INFECTIOUS DISEASES
  • CLIMATE CHANGE AND VECTOR-BORNE DISEASES
  • MALARIA
    • INCIDENCES OF MALARIA
      • Global Risk for Malaria
    • CAUSES OF MALARIA
      • Symptoms of Malaria
    • GLOBAL MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS
      • TABLE 75: GLOBAL MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • DIAGNOSIS OF MALARIA
      • TABLE 76: GLOBAL MARKET FOR MALARIAL DIAGNOSTIC PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • TREATMENT OF MALARIA
      • TABLE 77: CURRENT PHARMACEUTICALS FOR TREATMENT OF MALARIA, WITH TREATMENT AND MANUFACTURER, 2015
      • TABLE 78: GLOBAL MARKET FOR MALARIAL PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • REGIONAL ANALYSIS
      • TABLE 79: REGIONAL MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
      • FIGURE 8: REGIONAL MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, 2016 AND 2021 (%)
    • THE AMERICAS
      • TABLE 80: AMERICAS MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
      • Malarial Diagnostic Product Market in the Americas
        • TABLE 81: AMERICAS MARKET FOR MALARIAL DIAGNOSTIC PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)
      • Malarial Pharmaceutical Market in the Americas
        • TABLE 82: AMERICAS MARKET FOR MALARIAL PHARMACEUTICAL PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)
    • EMRA
      • TABLE 83: EMRA MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
      • Malarial Diagnostic Product Market in EMRA
        • TABLE 84: EMRA MARKET FOR MALARIAL DIAGNOSTIC PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)
      • Malarial Pharmaceutical Product Market in the EMRA
        • TABLE 85: EMRA MARKET FOR MALARIAL PHARMACEUTICAL PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)
    • ASIA
      • TABLE 86: ASIAN MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
      • TABLE 87: ASIAN MARKET FOR MALARIAL DIAGNOSTIC PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)
      • TABLE 88: ASIAN MARKET FOR MALARIAL PHARMACEUTICAL PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)
      • TABLE 89: CURRENT AND PARASITIC PHARMACEUTICALS WITH TRADE NAME, GENERIC NAME, MANUFACTURER AND AREA OF TREATMENT, 2014
  • MARKET FOR ANTIPARASITIC PHARMACEUTICALS
  • OPPORTUNITIES IN THE MALARIAL DISEASE MARKET
    • DIAGNOSTIC TESTING

CHAPTER 8 - EMERGING TECHNOLOGY AND PHARMACEUTICALS

  • GLAXOSMITHKLINE/NOVARTIS TRANSACTION
    • HEPATITIS C
      • TABLE 90: FDA-APPROVED PHARMACEUTICALS TO TREAT HCV, 2011-2015
      • TABLE 91: PHARMACEUTICALS IN CLINICAL TRIALS FOR HCV, 2015
      • FIGURE 9: RESEARCH LANDSCAPE FOR HBV PHARMACEUTICALS BY TYPE, 2015 (%)
  • DENGUE VIRUS VACCINE
    • MALARIA
      • TABLE 92: PHASE II & III PIPELINE FOR MALARIAL TREATMENTS, 2015
      • BASILEA PHARMACEUTICA
      • POLYPHOR
      • REMPEX PHARMA
      • HIV
      • ATTACHMENT INHIBITORS
      • GENE MODIFICATION
  • PHARMACEUTICAL TREATMENT PRODUCT PIPELINE
    • TABLE 93: INFECTIOUS DISEASES PHARMACEUTICAL PRODUCT PIPELINE, BY DISEASE, 2015

CHAPTER 9 - PATENT ANALYSIS

  • PATENT ANALYSIS
    • PATENT EXPIRATIONS
      • TABLE 94: U.S. PHARMACEUTICAL PATENT EXPIRY, 2010-2031
    • PHARMACEUTICAL PATENTS, BY PATENT NUMBER, DISEASE, COMPANY, DESCRIPTION AND APPROVAL DATE
      • TABLE 95: INFECTIOUS DISEASES PHARMACEUTICAL AND VACCINE PATENTS, JAN. 2015 TO SEPT. 2015
    • PATENTS ISSUED BY COMPANY
      • TABLE 96: INFECTIOUS DISEASES PHARMACEUTICAL AND VACCINE PRODUCT PATENTS BY COMPANY, JAN. 2015 TO SEPT. 2015
    • INFECTIOUS DISEASES PATENTS ISSUED, BY DISEASE
      • TABLE 97: PATENTS ISSUED FOR VACCINE AND TREATMENT OF INFECTIOUS DISEASES BY DISEASE, JAN. 2015 TO SEPT. 2015 (NUMBER/%)
      • TABLE 98: INFECTIOUS DISEASES VACCINE AND PHARMACEUTICAL PATENTS BY DISEASE ISSUED BETWEEN JAN. 2015 AND SEPT. 2015 (%)

CHAPTER 10 - COMPANY DIRECTORY

  • ABBOTT LABORATORIES
    • BUSINESS OVERVIEW
      • TABLE 99: ABBOTT PHARMACEUTICAL PRODUCTS
    • PRODUCTS
      • TABLE 100: ABBOTT DIAGNOSTIC PRODUCTS
  • ABBVIE INC.
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 101: ABBVIE PHARMACEUTICAL PRODUCTS
  • ALLERGAN (FORMERLY ACTAVIS)
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 102: ALLERGAN PHARMACEUTICAL PRODUCTS
  • ALERE
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 103: ALERE DIAGNOSTIC PRODUCTS
  • ALFA SCIENTIFIC DESIGNS
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 104 ALFA SCIENTIFIC DESIGNS' DIAGNOSTIC PRODUCTS
  • ATLAS LINK BIOTECH CO. LTD.
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 105: ATLAS LINK BIOTECH DIAGNOSTIC'S PRODUCTS
  • ASTRAZENECA
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 106: ASTRAZENECA PHARMACEUTICAL'S PRODUCTS
  • AUROBIND PHARMA LTD.
    • BUSINESS OVERVIEW
    • BAXTER INTERNATIONAL INC.
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 107: BAXTER PHARMACEUTICAL'S PRODUCTS
  • BAYER AG
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 108: BAYER PHARMACEUTICAL'S PRODUCTS
  • BECTON DICKINSON
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 109: BECTON DICKINSON DIAGNOSTIC'S PRODUCTS
  • BIO-RAD LABORATORIES
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 110: BIO-RAD DIAGNOSTIC'S PRODUCTS
  • BOEHRINGER INGELHEIM GMBH
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 111: BOEHRINGER INGELHEIM PHARMACEUTICAL'S PRODUCTS
  • BRISTOL-MYERS SQUIBB COMPANY
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 112: BRISTOL-MYERS SQUIBB'S PHARMACEUTICAL PRODUCTS
  • CEPHEID
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 113: CEPHEID DIAGNOSTIC'S PRODUCTS
  • CREATIVE PEPTIDES
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 114: CREATIVE PEPTIDE'S DIAGNOSTIC PRODUCTS
  • CRUCELL NV
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 115: CRUCELL'S VACCINE PRODUCTS
  • CUBIST PHARMACEUTICALS (SEE MERCK)
  • DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS INC.
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 116: DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS' DIAGNOSTIC PRODUCTS
  • DIASORIN
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 117: DIASORIN DIAGNOSTIC'S PRODUCTS
  • FIRST DIAGNOSTIC CORP.
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 118: FIRST DIAGNOSTIC'S PRODUCTS
  • FOCUS DIAGNOSTICS
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 119: FOCUS DIAGNOSTIC'S PRODUCTS
  • FOREST LABORATORIES (SEE ALLERGAN)
  • GILEAD SCIENCES INC.
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 120: GILEAD SCIENCE'S PHARMACEUTICAL PRODUCTS
  • GLAXOSMITHKLINE
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 121: GLAXOSMITHKLINE PHARMACEUTICAL'S VACCINE PRODUCTS
  • HOLOGIC INC.
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 122: HOLOGIC DIAGNOSTIC'S PRODUCTS
  • HOME ACCESS HEALTH CORP.
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 123: HOME ACCESS HEALTH'S DIAGNOSTICS PRODUCTS
  • IDENIX PHARMACEUTICALS (SEE MERCK)
  • IMMUNOSTICS INC.
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 124: IMMUNOSTIC'S DIAGNOSTIC PRODUCTS
  • JANSSEN THERAPEUTICS
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 125: JANSSEN THERAPEUTIC'S PHARMACEUTICAL PRODUCTS
  • LUPIN PHARMACEUTICALS INC.
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 126: LUPIN'S PHARMACEUTICAL PRODUCTS
  • MANGALAM DRUGS & ORGANICS LTD.
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 127 MANGALAM'S PHARMACEUTICAL PRODUCTS
  • MEDMIRA INC
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 128: MEDMIRA'S DIAGNOSTIC PRODUCTS
  • MELINTA THERAPEUTICS (FORMERLY RIB-X PHARMACEUTICALS)
    • BUSINESS OVERVIEW
  • MERCK & COMPANY INC.
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 129: MERCK'S VACCINE PRODUCTS
      • TABLE 130: MERCK'S PHARMACEUTICAL PRODUCTS
  • MERIDIAN BIOSCIENCE INC.
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 131: MERIDIAN BIOSCIENCE'S DIAGNOSTIC PRODUCTS
  • MYLAN PHARMACEUTICALS
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 132: MYLAN'S PHARMACEUTICAL PRODUCTS
  • NOVARTIS CORP.
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 133: NOVARTIS' DIAGNOSTIC PRODUCTS
      • TABLE 134: NOVARTIS' PHARMACEUTICAL PRODUCTS
  • ORASURE TECHNOLOGIES INC.
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 135: ORASURE'S DIAGNOSTIC PRODUCTS
  • ORTHO CLINICAL DIAGNOSTICS
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 136: ORTHO'S CLINICAL DIAGNOSTICS DIAGNOSTIC PRODUCTS
  • PARATEK PHARMACEUTICALS
    • BUSINESS OVERVIEW
  • PFIZER INC.
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 137: PFIZER'S VACCINE PRODUCTS
      • TABLE 138: PFIZER'S PHARMACEUTICAL PRODUCTS
  • PRINCETON BIOMEDITECH CORP.
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 139: PRINCETON BIOMEDICTECH'S DIAGNOSTIC PRODUCTS
  • PROTEIN SCIENCES CORP.
    • BUSINESS OVERVIEW
  • QUIDEL CORP.
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 140: QUIDEL'S DIAGNOSTIC PRODUCTS
  • QIAGEN N.V.
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 141: QIAGEN'S DIAGNOSTIC PRODUCTS
  • REMEL/THERMOFISHER SCIENTIFIC
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 142: REMEL'S DIAGNOSTIC PRODUCTS
  • ROCHE LABORATORIES (HOFFMANN-LA ROCHE INC.)
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 143: ROCHE'S DIAGNOSTIC PRODUCTS
      • TABLE 144: ROCHE'S PHARMACEUTICAL PRODUCTS
  • ROMARK LABORATORIES
    • BUSINESS OVERVIEW
  • SANDOZ
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 145: SANDOZ'S PHARMACEUTICAL PRODUCTS
  • SANOFI PASTEUR
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 146: SANOFI PASTEUR'S VACCINE PRODUCTS
  • SCICLONE PHARMACEUTICALS
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 147: SCICLONE'S PHARMACEUTICAL PRODUCTS
  • SHANGHAI KEHUA BIO-ENGINEERING CO. LTD.
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 148: SHANGHAI KEHUA'S DIAGNOSTIC PRODUCTS
  • STANDARD DIAGNOSTICS INC.
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 149: STANDARD DIAGNOSTICS' DIAGNOSTIC PRODUCTS
  • TETRAPHASE PHARMACEUTICALS
  • THE MEDICINE COMPANY
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 150: THE MEDICINE COMPANY'S PHARMACEUTICALS
  • TRINITY BIOTECH PLC
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 151: TRINITY BIOTECH'S DIAGNOSTIC PRODUCTS
  • VERTEX PHARMACEUTICALS
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 152: VERTEX'S PHARMACEUTICAL PRODUCTS
  • VIIV HEALTHCARE
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 153: VIIV HEALTHCARE'S PHARMACEUTICAL PRODUCTS
  • ZEUS SCIENTIFIC
    • BUSINESS OVERVIEW
    • PRODUCTS
      • TABLE 154: ZEUS SCIENTIFIC'S DIAGNOSTIC PRODUCTS

CHAPTER 11 - APPENDIX A COMPANY LISTINGS BY TYPE

  • TABLE 155: COMPANY LISTINGS BY TYPE, COMPANY, INDICATION AND NAME

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL MARKET FOR INFECTIOUS DISEASES DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • TABLE 1: GLOBAL PERCENTAGE OF DEATHS BY TYPE OF DISEASE, CAUSE, INCOME LEVEL, 2012* (%)
    • TABLE 2: SELECTED WORLDWIDE MAJOR INFECTIOUS DISEASES, 2013* (NUMBER OF CASES, TREATMENT OPTIONS)
    • TABLE 3: GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • TABLE 4: GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE VACCINE PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • TABLE 5: GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • TABLE 6: SELECTED MERGERS AND ACQUISITIONS, 2012 TO 2015 ($ MILLIONS)
    • TABLE 7: GLOBAL MARKET FOR INFECTIOUS DISEASE VACCINE PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • TABLE 8: GLOBAL MARKET FOR INFECTIOUS DISEASE VACCINES BY DISEASE, THROUGH 2021 ($ MILLIONS)
    • TABLE 9: VIRUSES, THE DISEASES THEY CAUSE, AND AVAILABLE VACCINES
    • TABLE 10: BACTERIA, THE DISEASES THEY CAUSE, AND AVAILABLE VACCINES
    • TABLE 11: IMMUNIZATION SCHEDULE FOR CHILDREN FROM BIRTH TO 6 MONTHS IN THE U.S.
    • TABLE 12: IMMUNIZATION SCHEDULE FOR CHILDREN FROM 12 MONTHS, TO 4 YEARS TO 6 YEARS IN THE U.S.
    • TABLE 13: IMMUNIZATION SCHEDULE FOR CHILDREN AND ADOLESCENTS FROM 7 YEARS TO 18 YEARS IN THE U.S.
    • TABLE 14: TOP-SELLING INFECTIOUS DISEASE VACCINES WITH APPLICATION, MANUFACTURER AND REVENUE, 2014
    • TABLE 15: REGIONAL MARKETS FOR VACCINES, THROUGH 2021 ($ MILLIONS)
    • TABLE 16: AMERICAS MARKET FOR INFECTIOUS DISEASE VACCINES BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 17: EMRA MARKET FOR INFECTIOUS DISEASE VACCINES BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 18: ASIAN MARKET FOR INFECTIOUS DISEASE VACCINES BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 19: GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • TABLE 20: PATENT EXPIRY BY PRODUCT, INDICATION, MANUFACTURER AND DATE OF PATENT EXPIRY
    • TABLE 21: GLOBAL MARKET FOR HEPATITIS DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • TABLE 22: GLOBAL MARKET SHARE FOR HEPATITIS B AND C DIAGNOSTIC PRODUCT BY TYPE OF TEST AND REVENUES, 2015 ($ MILLIONS/%)
    • TABLE 23: CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HEPATITIS B AND C BY BRAND NAME AND MANUFACTURER, 2015
    • TABLE 24: GLOBAL MARKET FOR HEPATITIS B AND C TREATMENT MANUFACTURER MARKET STANDING BY REVENUES, 2015 ($ MILLIONS/RANK)
    • TABLE 25: PHARMACEUTICALS FOR THE TREATMENT OF HEPATITIS B AND C, 2015
    • TABLE 26: GLOBAL MARKET FOR HBV AND HCV PHARMACEUTICALS, THROUGH 2021 ($ MILLIONS)
    • TABLE 27: GLOBAL MARKET FOR HSV DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • TABLE 28: CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HSV BY BRAND NAME, TYPE AND MANUFACTURER, 2015
    • TABLE 29: DRUGS USED TO TREAT HSV BY BRAND NAME, GENERIC NAME AND MANUFACTURER
    • TABLE 30: GLOBAL MARKET FOR HIV DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • TABLE 31: COMBINATION DRUGS APPROVED FOR HAART
    • TABLE 32: GLOBAL MARKET FOR HPV DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • TABLE 33: CANCERS LINKED TO HPV INFECTION, BY TYPE AND PERCENT OF FREQUENCY
    • TABLE 34: CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HPV BY BRAND NAME, TYPE AND MANUFACTURER, 2015
    • TABLE 35: DRUGS USED TO TREAT HPV BY BRAND NAME, GENERIC NAME AND MANUFACTURER
    • TABLE 36: RSV DIAGNOSTIC PRODUCTS BY BRAND NAME, MANUFACTURER AND TYPE, 2015
    • TABLE 37: GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • TABLE 38: GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • TABLE 39: REGIONAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • TABLE 40: REGIONAL MARKET FOR VIRAL DIAGNOSTIC PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • TABLE 41: REGIONAL MARKET FOR VIRAL PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • TABLE 42: AMERICAS MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 43: AMERICAS MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 44: EMRA MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 45: EMRA MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 46: CURRENTLY USED HEPATITIS DRUGS IN THE SOUTHEAST ASIAN REGION, BY PERCENT OF USE, 2012*
    • TABLE 47: ASIAN MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 48: ASIAN MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 49: NEGLECTED TROPICAL BACTERIAL INFECTIOUS DISEASES
    • TABLE 50: GLOBAL MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • TABLE 51: GLOBAL MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTICS, THROUGH 2021 ($ MILLIONS)
    • TABLE 52: GLOBAL MARKET FOR BACTERIAL INFECTIOUS DISEASES PHARMACEUTICALS, THROUGH 2021 ($ MILLIONS)
    • TABLE 53: CURRENTLY AVAILABLE CHLAMYDIA TESTS BY BRAND NAME, TYPE AND MANUFACTURER, 2015
    • TABLE 54: CURRENT MEDICATIONS USED TO TREAT CHLAMYDIA
    • TABLE 55: GONORRHEA DIAGNOSTIC PRODUCT AND MANUFACTURERS
    • TABLE 56: MAJOR GONORRHEA TREATMENT MANUFACTURERS AND PRODUCTS
    • TABLE 57: STAGES OF SYPHILIS
    • TABLE 58: CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF SYPHILIS BY BRAND NAME, TYPE AND MANUFACTURER, 2012
    • TABLE 59: GLOBAL MARKET FOR TB DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • TABLE 60: GLOBAL MARKET FOR TB DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 61: ANTIBIOTICS: YEAR OF INTRODUCTION, YEAR OF RESISTANCE OBSERVED, MODE OF ACTION AND TARGET SPECIES
    • TABLE 62: ANTIBIOTICS APPROVED FOR USE IN FOOD-PRODUCING ANIMALS BY DRUG CLASS, POUNDS USED, AND PERCENTAGE OF TOTAL, 2009* (POUNDS/%)
    • TABLE 63: ANTIBIOTIC-RESISTANT ORGANISMS AND DRUG CLASSES AFFECTED
    • TABLE 64: REGIONAL MARKET FOR BACTERIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • TABLE 65: AMERICAS MARKET FOR BACTERIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • TABLE 66: AMERICAS MARKET FOR BACTERIAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 67: AMERICAS MARKET FOR BACTERIAL INFECTION PHARMACEUTICAL PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 68: EMRA MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • TABLE 69: EMRA MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 70: EMRA MARKET FOR BACTERIAL INFECTIOUS DISEASES PHARMACEUTICAL PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 71: ASIAN MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • TABLE 72: ASIAN MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 73: ASIAN MARKET FOR BACTERIAL INFECTIOUS DISEASES PHARMACEUTICAL PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 74: NEGLECTED TROPICAL PARASITIC INFECTIOUS DISEASES
    • TABLE 75: GLOBAL MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • TABLE 76: GLOBAL MARKET FOR MALARIAL DIAGNOSTIC PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • TABLE 77: CURRENT PHARMACEUTICALS FOR TREATMENT OF MALARIA, WITH TREATMENT AND MANUFACTURER, 2015
    • TABLE 78: GLOBAL MARKET FOR MALARIAL PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • TABLE 79: REGIONAL MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • TABLE 80: AMERICAS MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • TABLE 81: AMERICAS MARKET FOR MALARIAL DIAGNOSTIC PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 82: AMERICAS MARKET FOR MALARIAL PHARMACEUTICAL PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 83: EMRA MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • TABLE 84: EMRA MARKET FOR MALARIAL DIAGNOSTIC PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 85: EMRA MARKET FOR MALARIAL PHARMACEUTICAL PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 86: ASIAN MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • TABLE 87: ASIAN MARKET FOR MALARIAL DIAGNOSTIC PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 88: ASIAN MARKET FOR MALARIAL PHARMACEUTICAL PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 89: CURRENT AND PARASITIC PHARMACEUTICALS WITH TRADE NAME, GENERIC NAME, MANUFACTURER AND AREA OF TREATMENT, 2014
    • TABLE 90: FDA-APPROVED PHARMACEUTICALS TO TREAT HCV, 2011-2015
    • TABLE 91: PHARMACEUTICALS IN CLINICAL TRIALS FOR HCV, 2015
    • TABLE 92: PHASE II & III PIPELINE FOR MALARIAL TREATMENTS, 2015
    • TABLE 93: INFECTIOUS DISEASES PHARMACEUTICAL PRODUCT PIPELINE, BY DISEASE, 2015
    • TABLE 94: U.S. PHARMACEUTICAL PATENT EXPIRY, 2010-2031
    • TABLE 95: INFECTIOUS DISEASES PHARMACEUTICAL AND VACCINE PATENTS, JAN. 2015 TO SEPT. 2015
    • TABLE 96: INFECTIOUS DISEASES PHARMACEUTICAL AND VACCINE PRODUCT PATENTS BY COMPANY, JAN. 2015 TO SEPT. 2015
    • TABLE 97: PATENTS ISSUED FOR VACCINE AND TREATMENT OF INFECTIOUS DISEASES BY DISEASE, JAN. 2015 TO SEPT. 2015 (NUMBER/%)
    • TABLE 98: INFECTIOUS DISEASES VACCINE AND PHARMACEUTICAL PATENTS BY DISEASE ISSUED BETWEEN JAN. 2015 AND SEPT. 2015 (%)
    • TABLE 99: ABBOTT PHARMACEUTICAL PRODUCTS
    • TABLE 100: ABBOTT DIAGNOSTIC PRODUCTS
    • TABLE 101: ABBVIE PHARMACEUTICAL PRODUCTS
    • TABLE 102: ALLERGAN PHARMACEUTICAL PRODUCTS
    • TABLE 103: ALERE DIAGNOSTIC PRODUCTS
    • TABLE 104: ALFA SCIENTIFIC DESIGNS' DIAGNOSTIC PRODUCTS
    • TABLE 105: ATLAS LINK BIOTECH DIAGNOSTIC'S PRODUCTS
    • TABLE 106: ASTRAZENECA PHARMACEUTICAL'S PRODUCTS
    • TABLE 107: BAXTER PHARMACEUTICAL'S PRODUCTS
    • TABLE 108: BAYER PHARMACEUTICAL'S PRODUCTS
    • TABLE 109: BECTON DICKINSON DIAGNOSTIC'S PRODUCTS
    • TABLE 110: BIO-RAD DIAGNOSTIC'S PRODUCTS
    • TABLE 111: BOEHRINGER INGELHEIM PHARMACEUTICAL'S PRODUCTS
    • TABLE 112: BRISTOL-MYERS SQUIBB'S PHARMACEUTICAL PRODUCTS
    • TABLE 113: CEPHEID DIAGNOSTIC'S PRODUCTS
    • TABLE 114: CREATIVE PEPTIDE'S DIAGNOSTIC PRODUCTS
    • TABLE 115: CRUCELL'S VACCINE PRODUCTS
    • TABLE 116: DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS' DIAGNOSTIC PRODUCTS
    • TABLE 117: DIASORIN DIAGNOSTIC'S PRODUCTS
    • TABLE 118: FIRST DIAGNOSTIC'S PRODUCTS
    • TABLE 119: FOCUS DIAGNOSTIC'S PRODUCTS
    • TABLE 120: GILEAD SCIENCE'S PHARMACEUTICAL PRODUCTS
    • TABLE 121: GLAXOSMITHKLINE PHARMACEUTICAL'S VACCINE PRODUCTS
    • TABLE 122: HOLOGIC DIAGNOSTIC'S PRODUCTS
    • TABLE 123: HOME ACCESS HEALTH'S DIAGNOSTICS PRODUCTS
    • TABLE 124: IMMUNOSTIC'S DIAGNOSTIC PRODUCTS
    • TABLE 125: JANSSEN THERAPEUTIC'S PHARMACEUTICAL PRODUCTS
    • TABLE 126: LUPIN'S PHARMACEUTICAL PRODUCTS
    • TABLE 127: MANGALAM'S PHARMACEUTICAL PRODUCTS
    • TABLE 128: MEDMIRA'S DIAGNOSTIC PRODUCTS
    • TABLE 129: MERCK'S VACCINE PRODUCTS
    • TABLE 130: MERCK'S PHARMACEUTICAL PRODUCTS
    • TABLE 131: MERIDIAN BIOSCIENCE'S DIAGNOSTIC PRODUCTS
    • TABLE 132: MYLAN'S PHARMACEUTICAL PRODUCTS
    • TABLE 133: NOVARTIS' DIAGNOSTIC PRODUCTS
    • TABLE 134: NOVARTIS' PHARMACEUTICAL PRODUCTS
    • TABLE 135: ORASURE'S DIAGNOSTIC PRODUCTS
    • TABLE 136: ORTHO'S CLINICAL DIAGNOSTICS DIAGNOSTIC PRODUCTS
    • TABLE 137: PFIZER'S VACCINE PRODUCTS
    • TABLE 138: PFIZER'S PHARMACEUTICAL PRODUCTS
    • TABLE 139: PRINCETON BIOMEDICTECH'S DIAGNOSTIC PRODUCTS
    • TABLE 140: QUIDEL'S DIAGNOSTIC PRODUCTS
    • TABLE 141: QIAGEN'S DIAGNOSTIC PRODUCTS
    • TABLE 142: REMEL'S DIAGNOSTIC PRODUCTS
    • TABLE 143: ROCHE'S DIAGNOSTIC PRODUCTS
    • TABLE 144: ROCHE'S PHARMACEUTICAL PRODUCTS
    • TABLE 145: SANDOZ'S PHARMACEUTICAL PRODUCTS
    • TABLE 146: SANOFI PASTEUR'S VACCINE PRODUCTS
    • TABLE 147: SCICLONE'S PHARMACEUTICAL PRODUCTS
    • TABLE 148: SHANGHAI KEHUA'S DIAGNOSTIC PRODUCTS
    • TABLE 149: STANDARD DIAGNOSTICS' DIAGNOSTIC PRODUCTS
    • TABLE 150: THE MEDICINE COMPANY'S PHARMACEUTICALS
    • TABLE 151: TRINITY BIOTECH'S DIAGNOSTIC PRODUCTS
    • TABLE 152: VERTEX'S PHARMACEUTICAL PRODUCTS
    • TABLE 153: VIIV HEALTHCARE'S PHARMACEUTICAL PRODUCTS
    • TABLE 154: ZEUS SCIENTIFIC'S DIAGNOSTIC PRODUCTS
    • TABLE 155: COMPANY LISTINGS BY TYPE, COMPANY, INDICATION AND NAME

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL MARKET SHARE FOR INFECTIOUS DISEASE DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PRODUCTS, 2016 AND 2021 (%)
    • FIGURE 1: GLOBAL IMMUNIZATION COVERAGE, 2014 (%)
    • FIGURE 2: VACCINE MANUFACTURING PROCESS
    • FIGURE 3: GLOBAL VACCINE MANUFACTURING MARKET, 2014 (%)
    • FIGURE 4: REGIONAL MARKET SHARE FOR VACCINES, 2016 AND 2021 (%)
    • FIGURE 5: GLOBAL MARKET SHARE FOR TOP PHARMACEUTICAL MANUFACTURERS IN THE HEPATITIS MARKET, 2015 (%)
    • FIGURE 6: REGIONAL MARKET SHARE FOR VIRAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, 2016 AND 2021 (%)
    • FIGURE 7: REGIONAL MARKET SHARE FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, 2016 AND 2021 (%)
    • FIGURE 8: REGIONAL MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, 2016 AND 2021 (%)
    • FIGURE 9: RESEARCH LANDSCAPE FOR HBV PHARMACEUTICALS BY TYPE, 2015 (%)
Back to Top